Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Healthy Volunteers
Interventions: Testosterone, Goserelin acetate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anorexia Nervosa, Eating Disorder, Anxiety, Depression
Interventions: Testosterone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Hypogonadism
Interventions: Androxal (enclomiphene citrate), Testosterone; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Coronary Artery Disease
Interventions: AndroGel 5 Grams, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinal Cord Injury
Interventions: Natesto testosterone intranasal gel, Ayr Saline Nasal Gel; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hypogonadism
Interventions: Testosterone gel 1.62%; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Prostate Cancer
Interventions: Leuprolide acetate 22.5 mg depot, GP-Pharm SA; Drug
Lead sponsor: GP-Pharm; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 25
States / cities: San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more

Conditions: Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
Interventions: Aveed Injectable Product, Fortesta, Testim; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more

Conditions: Hypogonadism, Benign Prostatic Hyperplasia
Interventions: Dutasteride, Testosterone gel, Placebo dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 50 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Adult Male Hypogonadism
Interventions: Testosterone gel (FE 999303); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Huntsville, Alabama • Newport Beach, California • San Diego, California + 14 more

Conditions: Contraception
Interventions: Nestorone gel, Testosterone Gel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
Interventions: Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection; Drug · Other
Lead sponsor: The Stone Research Foundation for Sports Medicine and Arthritis; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spinal Cord Injury, Hypogonadism
Interventions: Testosterone Transdermal System (Androderm 5 mg patch); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Prostate Cancer
Interventions: Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate); Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more

Conditions: Aging, Frailty, Osteoporosis
Interventions: testosterone; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hypogonadism, Male, Kidney Disease, Chronic
Interventions: Jatenzo Pill; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Dihydrotestosterone, Testosterone, Hair Loss
Interventions: Creatine Monohydrate Supplementation, Placebo Supplementation; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 35 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 10 more

Conditions: Hypogonadism
Interventions: Topical Testosterone Solution; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Encinitas, California • San Diego, California • Parker, Colorado + 18 more

Conditions: Prostate Cancer
Interventions: GTx-758 1000mg, Lupron Depot, GTx-758 2000mg; Drug
Lead sponsor: GTx; Industry
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more

Conditions: Cancer, Hypogonadism
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions: Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

Hormonal Factors in the Treatment of Anorexia Nervosa

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

Testosterone and Neural Function in Men With Spinal Cord Injury

Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

TRADE-Testosterone Replacement and Dutasteride Effectiveness

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

Testosterone Replacement Therapy in Chronic Spinal Cord Injury

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Testosterone Effects on Bone and Frailty

Testosterone Treatment in Men With Chronic Kidney Disease

COMbination of Bipolar Androgen Therapy and Nivolumab

Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair Assessments

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Prevalence of Hypogonadism in Male Cancer Patients

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial